Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 5/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.42 |
| ▸ | ADH1B | P00325 | 1/20 | 0.40 |
| ▸ | ADH1C | P00326 | 1/20 | 0.40 |
| ▸ | ADH1A | P07327 | 1/20 | 0.40 |
| ▸ | ADH4 | P08319 | 1/20 | 0.40 |
| ▸ | ADH7 | P40394 | 1/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316130 | 1.00 | OPRM1 (0.46) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL28216704 | 1.00 | OPRM1 (0.46) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL11579490 | 1.00 | OPRM1 (0.46) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL29518544 | 1.00 | OPRM1 (0.46) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL13555001 | 1.00 | OPRM1 (0.46) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL3315441 | 1.00 | OPRM1 (0.46) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL12424296 | 1.00 | OPRM1 (0.46) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL1142792 | 1.00 | OPRM1 (0.46) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL22817316 | 1.00 | OPRM1 (0.46) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL10447343 | 0.97 | OPRM1 (0.44) | OPRM1FAAHCNR1CNR2SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771712-B2 | Carborane compounds and methods of use thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2023-10-03 | — | — | US | disclosed |
| CN-112300099-A | Ketal derivatives of drugs, preparation method thereof, pharmaceutical compositions and uses | 南开大学 | 2021-02-02 | — | — | CN | disclosed |
| CN-109851485-A | The method and system of differential pressure heat coupling reaction rectifying production 2- methoxyl group -2- methyl heptane | 重庆大学 | 2019-06-07 | — | — | CN | disclosed |
| WO-2017174953-A1 | ALKYLATION METHOD | PIVERT (FR) | 2017-10-12 | — | — | WO | disclosed |
| US-9670410-B2 | Liquid crystal composition | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2017-06-06 | — | — | US | disclosed |
| US-20150137036-A1 | LIQUID CRYSTAL COMPOSITION | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2015-05-21 | — | — | US | disclosed |
| US-8633245-B2 | PAI-1 inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| EP-2132167-B1 | METHOD FOR THE PRODUCTION OF beta-KETONITRILES | BASF SE (DE) | 2013-12-25 | — | — | EP | disclosed |
| US-8501748-B2 | Method for the production of β-ketonitriles | BASF SE (DE) | 2013-08-06 | — | — | US | disclosed |
| US-8404160-B2 | Metallic ink | APPLIED NANOTECH HOLDINGS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| EP-1160250-A1 | Silicon derivative, liquid crystal composition and liquid crystal display | CHISSO CORPORATION (JP) | 2001-12-05 | — | — | EP | disclosed |
| EP-1114825-A1 | SILICON COMPOUNDS, LIQUID CRYSTAL COMPOSITIONS AND LIQUID CRYSTAL DISPLAYS | CHISSO CORPORATION (JP) | 2001-07-11 | — | — | EP | disclosed |
| EP-1010692-A1 | LIQUID-CRYSTAL COMPOUNDS HAVING LARGE VALUE OF PERMITTIVITY ANISOTROPY, LIQUID-CRYSTAL COMPOSITION CONTAINING THE SAME, AND LIQUID-CRYSTAL DISPLAY ELEMENT MADE USING THE LIQUID-CRYSTAL COMPOSITION | CHISSO CORPORATION (JP) | 2000-06-21 | — | — | EP | disclosed |
| US-5993690-A | Organosilicon compound, liquid crystal composition, and liquid-crystal display element | CHISSO CORPORATION (JP) | 1999-11-30 | — | — | US | disclosed |
| EP-0959060-A1 | CHLOROBENZENE DERIVATIVES, LIQUID-CRYSTAL COMPOSITION, AND LIQUID-CRYSTAL DISPLAY ELEMENTS | CHISSO CORPORATION (JP) | 1999-11-24 | — | — | EP | disclosed |
| EP-0872484-A1 | ORGANOSILICON COMPOUNDS, LIQUID-CRYSTAL COMPOSITION, AND LIQUID-CRYSTAL DISPLAY ELEMENT | CHISSO CORPORATION (JP) | 1998-10-21 | — | — | EP | disclosed |
| US-5324451-A | Excellent response and memory | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1994-06-28 | — | — | US | disclosed |
| EP-0329153-B1 | NOVEL LACTIC ACID DERIVATIVES AND LIQUID CRYSTAL COMPOSITIONS CONTAINING THE SAME | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1992-10-21 | — | — | EP | disclosed |
| EP-0329153-A2 | Novel lactic acid derivatives and liquid crystal compositions containing the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1989-08-23 | — | — | EP | disclosed |
| US-4376094-A | Method of disinfecting and a method for destroying bacteria and fungi using 2-substituted glutaraldehydes | STERLING DRUG INC. (US) | 1983-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771712-B2 | Carborane compounds and methods of use thereof | ESR2, GPER1, ESRRB | OPRM1 309/4885FAAH 1683/4885CNR1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.